IMA Wealth Inc. lifted its stake in shares of CRISPR Therapeutics AG (NASDAQ:CRSP – Get Rating) by 4.9% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 24,652 shares of the company’s stock after purchasing an additional 1,148 shares during the quarter. IMA Wealth Inc.’s holdings in CRISPR Therapeutics were worth $1,868,000 as of its most recent filing with the Securities and Exchange Commission.
Several other institutional investors also recently made changes to their positions in the company. Elkhorn Partners Limited Partnership increased its position in CRISPR Therapeutics by 180.0% in the 4th quarter. Elkhorn Partners Limited Partnership now owns 350 shares of the company’s stock valued at $27,000 after acquiring an additional 225 shares during the period. Kistler Tiffany Companies LLC boosted its position in shares of CRISPR Therapeutics by 6,250.0% in the fourth quarter. Kistler Tiffany Companies LLC now owns 381 shares of the company’s stock worth $29,000 after buying an additional 375 shares during the period. CI Investments Inc. acquired a new stake in shares of CRISPR Therapeutics in the third quarter worth $30,000. Clearstead Advisors LLC boosted its position in shares of CRISPR Therapeutics by 639.1% in the third quarter. Clearstead Advisors LLC now owns 340 shares of the company’s stock worth $38,000 after buying an additional 294 shares during the period. Finally, Newbridge Financial Services Group Inc. boosted its position in shares of CRISPR Therapeutics by 97.6% in the fourth quarter. Newbridge Financial Services Group Inc. now owns 565 shares of the company’s stock worth $43,000 after buying an additional 279 shares during the period. Institutional investors and hedge funds own 56.12% of the company’s stock.
Several equities analysts have weighed in on the company. Piper Sandler cut their target price on CRISPR Therapeutics from $180.00 to $115.00 and set an “overweight” rating on the stock in a report on Monday. Chardan Capital cut their target price on CRISPR Therapeutics from $171.00 to $168.00 in a report on Tuesday, May 10th. Barclays cut their target price on CRISPR Therapeutics from $107.00 to $99.00 in a report on Tuesday, May 10th. Stifel Nicolaus cut their target price on CRISPR Therapeutics to $64.00 in a report on Wednesday, February 16th. They noted that the move was a valuation call. Finally, Oppenheimer cut their target price on CRISPR Therapeutics from $172.00 to $150.00 in a report on Wednesday, May 11th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating and ten have given a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $118.63.
CRISPR Therapeutics (NASDAQ:CRSP – Get Rating) last posted its quarterly earnings data on Monday, May 9th. The company reported ($2.32) EPS for the quarter, missing analysts’ consensus estimates of ($1.94) by ($0.38). The business had revenue of $0.94 million for the quarter, compared to analyst estimates of $2.45 million. CRISPR Therapeutics had a return on equity of 12.77% and a net margin of 34.04%. The company’s quarterly revenue was up 74.4% on a year-over-year basis. During the same quarter in the prior year, the company earned ($1.51) earnings per share. Research analysts expect that CRISPR Therapeutics AG will post -8.97 earnings per share for the current year.
CRISPR Therapeutics Profile (Get Rating)
CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.
- Get a free copy of the StockNews.com research report on CRISPR Therapeutics (CRSP)
- Genesco Pops On Earnings But Don’t Expect A Rally
- The Insiders Are Selling Movado Group, But You Shouldn’t
- Beware The Rebound In Retail Stocks
- It’s A Good Time To Own Ralph Lauren (NYSE: RL)
- Block, Inc: Correcting for Negative Earnings
Receive News & Ratings for CRISPR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRISPR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.